Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279506 | 1.00 | CES1 (0.47) | CES1GLO1MAPTKMT2AMEN1 | |
| SCHEMBL276773 | 1.00 | CES1 (0.47) | CES1GLO1MAPTKMT2AMEN1 | |
| SCHEMBL184026 | 0.84 | DHODH (0.50) | CES1GLO1MAPTKMT2AMEN1 | |
| SCHEMBL18017493 | 0.84 | DHODH (0.50) | CES1GLO1MAPTKMT2AMEN1 | |
| SCHEMBL184027 | 0.84 | DHODH (0.50) | CES1GLO1MAPTKMT2AMEN1 | |
| SCHEMBL9382912 | 0.83 | CES1 (0.49) | CES1GLO1MAPTKMT2AMEN1 | |
| SCHEMBL9382917 | 0.83 | CES1 (0.49) | CES1GLO1MAPTKMT2AMEN1 | |
| SCHEMBL3571232 | 0.82 | NPSR1 (0.50) | GLO1MAPTKMT2AMEN1LMNA | |
| SCHEMBL3571235 | 0.82 | NPSR1 (0.50) | GLO1MAPTKMT2AMEN1LMNA | |
| SCHEMBL478613 | 0.82 | CES1 (0.61) | CES1MAPTKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105732634-A | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | 拜尔健康护理有限责任公司 | 2016-07-06 | — | — | CN | disclosed |
| CN-101365454-B | substituted 4-amino-pyrrolotriazine derivatives | BAYER HEALTHCARE LLC (US) | 2016-03-30 | — | — | CN | disclosed |
| US-8829185-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2014-09-09 | — | — | US | disclosed |
| EP-1957077-B1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20120165314-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2465505-A1 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | Bayer HealthCare LLC (US) | 2012-06-20 | — | — | EP | disclosed |
| US-8133995-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | BAYER HEALTHCARE LLV (US) | 2009-11-12 | — | — | US | disclosed |
| CN-101365454-A | Substituted 4-amino-pyrrolotriazine derivatives for the treatment of hyperproliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2009-02-11 | — | — | CN | disclosed |
| EP-1957077-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer HealthCare LLC (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007064883-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC. (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-0169712-B1 | NEW PYRIMIDINE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND COMPOSITION CONTAINING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-12-12 | — | — | EP | disclosed |
| US-4698340-A | TREATMENT OF CEREBROVASCULAR DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-06 | — | — | US | disclosed |
| EP-0169712-A2 | New pyrimidine derivatives, processes for preparation thereof and composition containing the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-29 | — | — | EP | disclosed |
| US-4243406-A | REDUCING INJURIES TO CROP PLANTS WHEN USING AN ALPHA-HALOACETANILIDE AS A HERBICIDE | MONSANTO COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165314-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | CDK4, FLT4, CDKL4 | CES1 4408/4885GLO1 2014/4885MAPT 1376/4885 |
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | CDK4, FLT4, CDKL4 | CES1 4408/4885GLO1 2014/4885MAPT 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.